The sepsis drug that was pulled by Indiana drug maker Eli Lilly and Co. could have worked, according to a new study conducted at the University of Nebraska Medical Center.
Equities reports that Andre Kalil, an associate professor in the UNMC Department of Internal Medicine studied Eli Lilly’s drug Xigris, which was taken off the market by the company in 2011 over concerns of its effectiveness.
ABC News reports that the company pulled the sepsis drug after doing a second clinical trial, which showed that the drug was only slightly better than a placebo.
In taking Xigris off the market, Eli Lilly and Co. has taken away the only drug that is specifically designed to fight sepsis. Dr. Greg Martin, director of the medical and coronary intensive care units at Emory University, stated:
“This was the first drug specifically licensed for sepsis, which leaves us essentially with nothing now.”
According to Equities, the new study, which was published in the July 17th edition of The Lancet Infectious Diseases, shows that, of 50,000 patients who took the drug between 2001 and 2011, the drug reduced the risk of death by 18 percent. Since the results of the study show that the drug did help, the study raises questions of if the drug should be put back on the market or not.
Currently, despite medical care, about one-third of patients who contract sepsis die. Dr. Kalil pointed out that as many people die from severe sepsis as heart attacks each year.
The Indianapolis Star reports, however, that Eli Lilly has no plans to bring the sepsis drug Xigris back on the market.
Check out more information about sepsis and Xigris below: